Castle biosciences stock.
The estimated Net Worth of David S Kabakoff is at least $76.2 Million dollars as of 17 June 2021. David Kabakoff owns over 30,000 units of Castle Biosciences stock worth over $11,536,949 and over the last 4 years he sold CSTL stock worth over $64,362,650. In addition, he makes $288,339 as Independent Director at Castle …
Stocks CSTL Overview Castle Biosciences Inc. U.S.: Nasdaq About Castle Biosciences Inc. Average price target from ratings: $ Full Ratings 52.55K (21.02% of Avg) 65 Day …Castle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for 25.00 expecting CSTL to rise to within 12 ...
The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.2 Ağu 2023 ... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health ... stock-based compensation expense, change in fair value of contingent ...But note: Castle Biosciences may not be the best stock to buy.So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).. Please note, the ...
Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...
Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.Find the latest Interpace Biosciences, Inc. (IDXG) stock quote, history, news and other vital information to help you with your stock trading and investing.Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 1 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 830 units of CSTL stock worth $17,355 on 10 June 2022.830 units of CSTL stock worth $17,355 on 10 June 2022.Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,642 on 14 July 2023.. The largest trade Kim's ever made was exercising 3,825 units of Castle Biosciences …
31 Eki 2023 ... About Castle Biosciences Inc (CSTL). Before we jump into Castle Biosciences Inc's stock price, history, target price and what caused it to ...
Under the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences. At closing, Castle will pay $65.0 million in initial consideration to AltheaDx ...
Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47. Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,070 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …Jul 7, 2023 · In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00. Below is ... Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersFind real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive …Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and ...Nov 14, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 …
News Castle Biosciences Inc. No significant news for in the past two years. Shares Sold Short 1.43 M Change from Last 28.06% Percent of Float 5.52% Stock Money Flow …
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. ... up to an additional $75.0 million in cash and common stock will be payable in connection with the ...These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...The estimated Net Worth of Mara G. Aspinall is at least $1.28 million dollars as of 2 June 2023. Ms. Aspinall owns over 3,825 units of Castle Biosciences stock worth over $485,681 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. ... Net loss for the third quarter, which includes non-cash stock-based compensation expense of $13.0 million, …
Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …
Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.
Nov 24, 2023 · Castle Biosciences Inc CSTL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ... registrant’s common stock on June 30, 2020, as reported by the Nasdaq Global Market. As of March 5, 2021, there were 24,978,424 shares of …Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...The estimated Net Worth of Mara G. Aspinall is at least $2.59 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,789,913 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Castle Biosciences Today's Change (-0.50%) -$0.10 Current Price $19.78 Key Data Points Market Cap $535M Day's Range $19.62 - $19.95 52wk Range $9.26 - …Future criteria checks 1/6. Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …
About the Castle Biosciences, Inc. stock forecast. As of 2023 November 23, Thursday current price of CSTL stock is 19.810$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Castle Biosciences stock price has been showing a declining tendency so we believe that …Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersThe 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...Instagram:https://instagram. used ford f150 lightningt rowe price capital appreciation etffduxxace branding Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting … margaritaville jimmy buffett jewelryhow to sell stock td ameritrade How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences stock trading at $18.06 per share, the total value of Castle Biosciences stock (market capitalization) is $486.00M. Castle Biosciences stock was originally listed at a price of $21.40 in Jul ... best vpn free for android FRIENDSWOOD, Texas, November 08, 2023--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major …Jun 15, 2023 · Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ... Jun. 03, 2022 5:05 PM ET Castle Biosciences, Inc. (CSTL) SA Transcripts. 140.86K Follower s. The following slide deck was published by Castle Biosciences, Inc. in conjunction with this event. View ...